Interferon alpha in the therapy of CML.
This paper summarizes the experience with interferon alpha (IFN alpha) as single-agent therapy and in combination gathered at M.D. Anderson Cancer Center. It also covers some of the laboratory research associated with these clinical studies.
Department of Clinical Immunology and Biological Therapy, University of Texas Cancer Center, M.D. Anderson Hospital, Houston.
M
M
Talpaz
H
H
Kantarjian
R
R
Kurzrock
J U
JU
Gutterman
D003131:Combined Modality Therapy; D003561:Cytarabine / Q000627:therapeutic use; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use*; D007371:Interferon-gamma / Q000627:therapeutic use; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy / Q000628:therapy*; D011994:Recombinant Proteins
D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D003561:Cytarabine; D007371:Interferon-gamma